Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

FOXP3+ T regulatory lymphocytes in primary melanoma are associated with BRAFmutation but not with response to BRAF inhibitor

Autor: Leslie, Connull, Bowyer, Samantha E., White, Alison, Grieu-Iacopetta, Fabienne, Trevenen, Michelle, Iacopetta, Barry, Amanuel, Benhur, Millward, Michael

Publikováno v: Pathology; October 2015, Vol. 47 Issue: 6 p557-563, 7p

Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial.

Autor: Grivas P; Division of Hematology/Oncology, Department of Medicine, University of Washington, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington., Garralda E; Medical Oncology Department, Vall d'Hebron Hospital Campus and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Mellinghoff IK; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York., Goyal L; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts., Harding JJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Weill Cornell Medical College, New York, New York., Dees EC; Lineberger Comprehensive Cancer Center and Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Bahleda R; Drug Development Department, Institut Gustave Roussy, Villejuif, France., Azad NS; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland., Karippot A; Cancer Treatment Centers of America, Tulsa, Oklahoma., Kurzrock R; Center for Personalized Cancer Therapy, University of California San Diego, Moores Cancer Center, La Jolla, California., Tabernero J; Medical Oncology Department, Vall d'Hebron Hospital Campus and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Kononen J; Docrates Cancer Center, Helsinki, Finland., Ng MCH; Division of Medical Oncology, National Cancer Centre, Singapore, Singapore., Mehta R; GI Medical Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida., Uboha NV; Division of Hematology and Oncology, Department of Medicine, University of Wisconsin Carbone Cancer Center, Madison, Wisconsin., Bigot F; Medical Oncology Department, Institut de Cancérologie de l'Ouest, Angers, France., Boni V; START Madrid, Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain., Bowyer SE; Linear Clinical Research, Perth, Australia., Breder V; NN Blokhin National Medical Research Center of Oncology, Ministry of Health, Moscow, Russian Federation., Cervantes A; Department of Medical Oncology, Hospital Clínico Universitario de Valencia, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain., Chan N; Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey., Cleary JM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Dhawan M; Division of Hematology and Oncology, University of California, San Francisco, California., Eefsen RL; Department of Oncology, Herlev Gentofte Hospital, Herlev, Denmark., Ewing J; Ironwood Cancer and Research Centers, Scottsdale, Arizona., Graham DM; The Christie NHS Foundation Trust, Manchester, United Kingdom.; Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom., Guren TK; Department of Oncology, Oslo University Hospital, Oslo, Norway., Won Kim J; Division of Hematology/Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea., Koynov K; Department of Medical Oncology, MHAT 'Serdika', Sofia, Bulgaria., Oh DY; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, South Korea., Redman R; Brown Cancer Center, University of Louisville, Louisville, Kentucky., Yen CJ; Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan., Spetzler D; Caris Life Sciences, Phoenix, Arizona., Roubaudi-Fraschini MC; Debiopharm International, Lausanne, Switzerland., Nicolas-Metral V; Debiopharm International, Lausanne, Switzerland., Ait-Sarkouh R; Debiopharm International, Lausanne, Switzerland., Zanna C; Debiopharm International, Lausanne, Switzerland., Ennaji A; Debiopharm International, Lausanne, Switzerland., Pokorska-Bocci A; Debiopharm International, Lausanne, Switzerland., Flaherty KT; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Oct 15; Vol. 30 (20), pp. 4572-4583.